House bill · H.R. 5160 (119th Congress)

Stem Cell Therapeutic and Research Reauthorization Act of 2025

U.S. House of Representatives

Latest action Jul 21, 2026

Sponsor: Christopher H. Smith (U.S. Representative, NJ-4, Republican)

Following needs an Agora account. You will sign in first, then come back to this page.

From Congress.gov and official rosters. This record was last updated Sep 8, 2026. About our data

Summary

Stem Cell Therapeutic and Research Reauthorization Act of 2025 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

Summary from the Congressional Research Service. How we handle summaries

Where it stands

Passed one of the two chambers; it still needs the other.

Introduced
In committee
Up for a vote
Passed one chamber
Passed
Enacted

Committee

House Committee on Energy and Commerce · U.S. House of Representatives

Your position on this bill

Choose the position closest to yours. You'll sign in or create an account to save it.

Cosponsors

Cosponsors listed on Congress.gov, shown A to Z.

Democratic11
Republican10

This bill has cosponsors from more than one party.

Shown in neutral colors by design; Agora is non-partisan.

S. 4109Stem Cell Therapeutic and Research Reauthorization Act of 2026Related bill

As identified by Congress.gov.

Full history

Jul 21, 2026
Sent to the executive
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
U.S. Senate
Jul 20, 2026
Considered Under Suspension of the rules. (consideration: cr H4642-4643)
Considered under suspension of the rules. (consideration: CR H4642-4643)
Jul 20, 2026
Considered Under Suspension of the rules. (consideration: cr H4642-4643)
Considered under suspension of the rules. (consideration: CR H4642-4643)
Jul 20, 2026
Considered Under Suspension of the rules. (consideration: cr H4642-4643)
Considered under suspension of the rules. (consideration: CR H4642-4643)
Jul 20, 2026
Debate - the House Proceeded With Forty Minutes of Debate on H.R. 5160.
DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
U.S. House of Representatives

Show full history (29 earlier events)

Jul 20, 2026
Passed a chamber
Motion to reconsider laid on the table Agreed to without objection.
Jul 20, 2026
Passed a chamber
Motion to reconsider laid on the table Agreed to without objection.
Jul 20, 2026
Passed a chamber
Motion to reconsider laid on the table Agreed to without objection.
Jul 20, 2026
Passed a chamber
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
U.S. House of Representatives
Jul 2, 2026
Placed on the Union Calendar, Calendar No. 629.
Jul 2, 2026
Placed on the Union Calendar, Calendar No. 629.
Jul 2, 2026
Placed on the Union Calendar, Calendar No. 629.
Jul 2, 2026
Reported out of committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
Jul 2, 2026
Reported out of committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
Jul 2, 2026
Reported out of committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
May 21, 2026
Committee vote
Committee Consideration and Mark-up Session Held
May 21, 2026
Committee vote
Committee Consideration and Mark-up Session Held
May 21, 2026
Committee vote
Committee Consideration and Mark-up Session Held
May 21, 2026
Reported out of committee
Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
May 21, 2026
Introduced
Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
U.S. House
May 21, 2026
Reported out of committee
Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
May 21, 2026
Reported out of committee
Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
May 13, 2026
In committee
Forwarded by Subcommittee to Full Committee by Voice Vote.
May 13, 2026
In committee
Forwarded by Subcommittee to Full Committee by Voice Vote.
May 13, 2026
In committee
Forwarded by Subcommittee to Full Committee by Voice Vote.
May 13, 2026
Committee vote
Subcommittee Consideration and Mark-up Session Held
May 13, 2026
Committee vote
Subcommittee Consideration and Mark-up Session Held
May 13, 2026
Committee vote
Subcommittee Consideration and Mark-up Session Held
Apr 2, 2026
Introduced
Introduced in U.S. House
U.S. House
Sep 4, 2025
Introduced
Introduced in House
U.S. House of Representatives
Sep 4, 2025
Referred to committee
Referred to the House Committee on Energy and Commerce.
U.S. House of Representatives
Sep 4, 2025
Referred to committee
Referred to the Subcommittee on Health.
Sep 4, 2025
Referred to committee
Referred to the Subcommittee on Health.
Sep 4, 2025
Referred to committee
Referred to the Subcommittee on Health.

Read the record

Read on Congress.gov (opens in a new tab) The official record on Congress.gov.